LifeStyle

• SK Bioscience launches development of antiviral nasal spray for COVID-19 prevention SEOUL -- SK Bioscience began developing an innovative technology to prevent viral infections and relieve symptoms through intranasal spray in a project funded by the Bill & Melinda Gates Foundation. The spray could slow the spread of COVID-19 once authorized as the first line of defense before vaccines or therapeutics are developed. When sprayed into the nose, a small protein creates a protective layer inside the upper respiratory tract and may alleviate symptoms of an establish 13 April 2022
• Abclon partners with state cancer center to develop CAR-T cell therapy for intractable solid cancer SEOUL -- South Korea's state cancer center will cooperate with Abclon, a domestic antibody-drug company, to develop a CAR-T cell therapy for intractable solid cancers. In CAR-T treatment, immune cells obtained from the patient's blood are genetically manipulated, cultured, and put back into the patient's body. CAR-T cell therapy uses T cells engineered with chimeric antigen receptors (CARs), which are receptor proteins that have been engineered to give immune cells the 8 April 2022
• State-run hospital treats leukemia patient with self-produced CAR-T treatment SEOUL -- South Korea's top state-run hospital has successfully treated an 18-year-old leukemia patient with self-produced CAR-T treatment in which immune cells obtained from the patient's blood are genetically manipulated, cultured, and put back into the patient's body. It was the first self-produced CAR-T treatment among domestic hospitals. CAR-T cell therapy uses T cells engineered with chimeric antigen receptors (CARs), which are receptor proteins that have been engin 5 April 2022
• Researchers develop rapid diagnosis technology to detect COVID-19 virus and mutantations SEOUL -- A state research body in South Korea has developed a rapid diagnosis technology that can detect COVID-19 mutant antigens. Researchers have transferred their technology to a private company for the commercialization of universal rapid test kits capable of detecting novel coronaviruses and mutations. As a transmembrane protein, angiotensin-converting enzyme 2 (mACE2) serves as the main entry point into cells for some coronaviruses. The Korea Research Institute of Chemical T 5 April 2022
• [INTERVIEW] Babitalk eyes overseas markets after success in domestic market with unique marketing SEOUL -- Babitalk, a mobile application that gives information about plastic surgery in South Korea, eyes overseas expansion especially in Southeast Asia, buoyed by fast domestic growth with unique non-traditional marketing that attracts consumers' attention with advertisements encouraging careful decision-making on plastic surgery. Babitalk is South Korea's No. 1 beauty medical information app that connects users with plastic surgeons and dermatologists and generates profit 4 April 2022
• KT unveils AI autonomous robots with safe plasma quarantine function SEOUL -- South Korea's largest telecom company KT unveiled two types of autonomous quarantine robots, small and large, to sterilize viruses and purify the air using a plasma method that can safely disinfect hospitals, schools and public facilities at all times even with people staying around. The global outbreak of a novel coronavirus prompted researchers to quickly develop autonomous quarantine robots that can roam about high-risk facilities. There are many kinds of autonomous 30 March 2022
• CJ Cheil Jedang reveals strategy to actively push for alternative meat production SEOUL -- CJ Cheil Jedang, a key subsidiary of South Korea's food and entertainment conglomerate CJ Group, revealed a business strategy to actively push for the production of alternative meat after it secured a stable supply source of cell culture media, a key raw material for cultured meat which is produced by in vitro cell culture of animal cells. "We will not only push to strengthen profitability through innovation in cost prices and cost structure but also begin our a 29 March 2022
• State health center signs pre-purchase contract for SK Bioscience's COVID-19 vaccine SEOUL -- South Korea's state health center has signed a pre-purchase contract for 10 million doses of a COVID-19 vaccine candidate codenamed GBP510 being developed by SK Bioscience, which aims to supply GBP510 from the second half of 2022 and obtain emergency use approval from the World Health Organization. GBP510 is South Korea's first vaccine candidate to receive state permission for Phase 3 clinical trials and the second in the world to demonstrate its effectiveness in 21 March 2022

처음이전7891011다음끝